Active Biotech AB (publ) (ACTI.ST)
SEK 0.1
(10.61%)
SEK 0.1
(10.61%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -33.2 Million SEK | 7.15% |
| 2022 | -35.75 Million SEK | 31.43% |
| 2021 | -52.14 Million SEK | -115.38% |
| 2020 | -24.21 Million SEK | 57.09% |
| 2019 | -56.42 Million SEK | -131.56% |
| 2018 | 178.79 Million SEK | -3.49% |
| 2017 | 185.26 Million SEK | 33.66% |
| 2016 | 138.6 Million SEK | 16.33% |
| 2015 | 119.14 Million SEK | 220.45% |
| 2014 | -98.91 Million SEK | 31.9% |
| 2013 | -145.25 Million SEK | -831.59% |
| 2012 | 19.85 Million SEK | 108.93% |
| 2011 | -222.36 Million SEK | -276.36% |
| 2010 | 126.08 Million SEK | 26.79% |
| 2009 | 99.44 Million SEK | -16.88% |
| 2008 | 119.63 Million SEK | 3.75% |
| 2007 | 115.31 Million SEK | -55.79% |
| 2006 | 260.85 Million SEK | 43.27% |
| 2005 | 182.07 Million SEK | 262.36% |
| 2004 | -112.14 Million SEK | -177.83% |
| 2003 | -40.36 Million SEK | 75.75% |
| 2002 | -166.47 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -22.8 Million SEK | 31.33% |
| 2024 Q3 | -6.2 Million SEK | 46.55% |
| 2024 Q2 | -11.6 Million SEK | 49.12% |
| 2023 FY | -33.2 Million SEK | 7.15% |
| 2023 Q1 | -26.1 Million SEK | 27.01% |
| 2023 Q3 | -2.2 Million SEK | 81.67% |
| 2023 Q2 | -12 Million SEK | 54.02% |
| 2023 Q4 | -33.2 Million SEK | -1409.09% |
| 2022 Q4 | -35.75 Million SEK | 29.19% |
| 2022 Q2 | -17.1 Million SEK | 54.52% |
| 2022 Q1 | -37.6 Million SEK | 27.9% |
| 2022 FY | -35.75 Million SEK | 31.43% |
| 2022 Q3 | -50.5 Million SEK | -195.32% |
| 2021 Q1 | -91.6 Million SEK | -278.32% |
| 2021 Q2 | -78.4 Million SEK | 14.41% |
| 2021 Q4 | -52.14 Million SEK | 23.65% |
| 2021 Q3 | -68.3 Million SEK | 12.88% |
| 2021 FY | -52.14 Million SEK | -115.38% |
| 2020 Q4 | -24.21 Million SEK | 19.02% |
| 2020 FY | -24.21 Million SEK | 57.09% |
| 2020 Q1 | -46.2 Million SEK | 18.13% |
| 2020 Q2 | -36.9 Million SEK | 20.13% |
| 2020 Q3 | -29.9 Million SEK | 18.97% |
| 2019 Q2 | -67.7 Million SEK | -134.26% |
| 2019 Q4 | -56.42 Million SEK | 16.53% |
| 2019 FY | -56.42 Million SEK | -131.56% |
| 2019 Q1 | 197.6 Million SEK | 10.52% |
| 2019 Q3 | -67.6 Million SEK | 0.15% |
| 2018 Q2 | 172.7 Million SEK | -18.27% |
| 2018 Q1 | 211.3 Million SEK | 14.06% |
| 2018 Q3 | 180.4 Million SEK | 4.46% |
| 2018 Q4 | 178.79 Million SEK | -0.89% |
| 2018 FY | 178.79 Million SEK | -3.49% |
| 2017 Q2 | 159.6 Million SEK | 9.39% |
| 2017 Q4 | 185.26 Million SEK | 8.85% |
| 2017 FY | 185.26 Million SEK | 33.66% |
| 2017 Q1 | 145.9 Million SEK | 5.27% |
| 2017 Q3 | 170.2 Million SEK | 6.64% |
| 2016 Q1 | 138.1 Million SEK | 15.91% |
| 2016 FY | 138.6 Million SEK | 16.33% |
| 2016 Q3 | 171.7 Million SEK | 10.28% |
| 2016 Q2 | 155.7 Million SEK | 12.74% |
| 2016 Q4 | 138.6 Million SEK | -19.28% |
| 2015 FY | 119.14 Million SEK | 220.45% |
| 2015 Q4 | 119.14 Million SEK | 39.35% |
| 2015 Q3 | 85.5 Million SEK | 159.88% |
| 2015 Q2 | 32.9 Million SEK | 166.46% |
| 2015 Q1 | -49.5 Million SEK | 49.96% |
| 2014 Q2 | -600 Thousand SEK | 99.12% |
| 2014 Q4 | -98.91 Million SEK | -240.84% |
| 2014 Q3 | 70.23 Million SEK | 11805.83% |
| 2014 Q1 | -68 Million SEK | 53.18% |
| 2014 FY | -98.91 Million SEK | 31.9% |
| 2013 Q4 | -145.25 Million SEK | -57.54% |
| 2013 Q3 | -92.2 Million SEK | 43.68% |
| 2013 FY | -145.25 Million SEK | -831.59% |
| 2013 Q1 | -244.8 Million SEK | -1333.0% |
| 2013 Q2 | -163.7 Million SEK | 33.13% |
| 2012 Q4 | 19.85 Million SEK | 106.43% |
| 2012 Q1 | -378.4 Million SEK | -70.17% |
| 2012 Q2 | -383.7 Million SEK | -1.4% |
| 2012 FY | 19.85 Million SEK | 108.93% |
| 2012 Q3 | -308.8 Million SEK | 19.52% |
| 2011 Q1 | -411.3 Million SEK | -426.2% |
| 2011 Q2 | -601.3 Million SEK | -46.19% |
| 2011 Q3 | -530.1 Million SEK | 11.84% |
| 2011 Q4 | -222.36 Million SEK | 58.05% |
| 2011 FY | -222.36 Million SEK | -276.36% |
| 2010 Q4 | 126.08 Million SEK | 171.68% |
| 2010 FY | 126.08 Million SEK | 26.79% |
| 2010 Q2 | -235.3 Million SEK | -112.75% |
| 2010 Q1 | -110.6 Million SEK | -211.22% |
| 2010 Q3 | -175.9 Million SEK | 25.24% |
| 2009 FY | 99.44 Million SEK | -16.88% |
| 2009 Q4 | 99.44 Million SEK | 0.0% |
| 2008 FY | 119.63 Million SEK | 3.75% |
| 2007 FY | 115.31 Million SEK | -55.79% |
| 2006 FY | 260.85 Million SEK | 43.27% |
| 2005 FY | 182.07 Million SEK | 262.36% |
| 2004 FY | -112.14 Million SEK | -177.83% |
| 2003 FY | -40.36 Million SEK | 75.75% |
| 2002 FY | -166.47 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| 2cureX AB (publ) | -13.4 Million SEK | -147.706% |
| Abliva AB (publ) | -57.24 Million SEK | 41.999% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -59.669% |
| AcouSort AB (publ) | -23.98 Million SEK | -38.414% |
| Alzinova AB (publ) | -21.22 Million SEK | -56.412% |
| Amniotics AB (publ) | -5.63 Million SEK | -489.489% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -55.032% |
| Aptahem AB (publ) | 2.9 Million SEK | 1241.426% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -1436.326% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 33.628% |
| BioInvent International AB (publ) | -236.3 Million SEK | 85.95% |
| BioArctic AB (publ) | -606.58 Million SEK | 94.527% |
| Biosergen AB | -1.88 Million SEK | -1663.144% |
| Biovica International AB (publ) | -58.73 Million SEK | 43.477% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 15.698% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 714.815% |
| Camurus AB (publ) | -1.16 Billion SEK | 97.151% |
| Cantargia AB (publ) | -139.74 Million SEK | 76.243% |
| Corline Biomedical AB | -17.01 Million SEK | -95.156% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -3496.966% |
| CombiGene AB (publ) | -101.44 Million SEK | 67.271% |
| Cyxone AB (publ) | -16.67 Million SEK | -99.16% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -1017.093% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 59.555% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 82.948% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -12.991% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 40.593% |
| Fluicell AB (publ) | -2.76 Million SEK | -1101.592% |
| Genovis AB (publ.) | -43.94 Million SEK | 24.444% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 60.354% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 124.646% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 89.911% |
| Mendus AB (publ) | -96.29 Million SEK | 65.522% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 60.355% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 75.968% |
| I-Tech AB | -83.26 Million SEK | 60.126% |
| Intervacc AB (publ) | -88.16 Million SEK | 62.341% |
| Kancera AB (publ) | -45.69 Million SEK | 27.34% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 59.612% |
| LIDDS AB (publ) | -13.51 Million SEK | -145.708% |
| Lipum AB (publ) | -8.46 Million SEK | -292.203% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -3.987% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 162.379% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -74.187% |
| Nanologica AB (publ) | -9.38 Million SEK | -253.643% |
| NextCell Pharma AB | -46.79 Million SEK | 29.046% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 50.389% |
| OncoZenge AB (publ) | -12.62 Million SEK | -162.929% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -540.813% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 261.872% |
| Saniona AB (publ) | 40.44 Million SEK | 182.083% |
| Simris Alg AB (publ) | 85.07 Million SEK | 139.024% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 26.576% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 33.512% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -150.96% |
| SynAct Pharma AB | -61.75 Million SEK | 46.242% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 90.049% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 119.991% |
| Xintela AB (publ) | -7.8 Million SEK | -325.15% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 74.362% |
| Ziccum AB (publ) | -2.13 Million SEK | -1453.58% |